Jeffrey L. Cummings

169.6k total citations · 57 hit papers
994 papers, 104.0k citations indexed

About

Jeffrey L. Cummings is a scholar working on Psychiatry and Mental health, Physiology and Molecular Biology. According to data from OpenAlex, Jeffrey L. Cummings has authored 994 papers receiving a total of 104.0k indexed citations (citations by other indexed papers that have themselves been cited), including 445 papers in Psychiatry and Mental health, 296 papers in Physiology and 138 papers in Molecular Biology. Recurrent topics in Jeffrey L. Cummings's work include Dementia and Cognitive Impairment Research (366 papers), Alzheimer's disease research and treatments (274 papers) and Cholinesterase and Neurodegenerative Diseases (118 papers). Jeffrey L. Cummings is often cited by papers focused on Dementia and Cognitive Impairment Research (366 papers), Alzheimer's disease research and treatments (274 papers) and Cholinesterase and Neurodegenerative Diseases (118 papers). Jeffrey L. Cummings collaborates with scholars based in United States, United Kingdom and Canada. Jeffrey L. Cummings's co-authors include Ziad Nasreddine, Simon Charbonneau, Howard Chertkow, Natalie A. Phillips, Victor Whitehead, Isabelle Collin, Michael S. Mega, Kate Zhong, Jeffrey Gornbein and Susan Rosenberg-Thompson and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Jeffrey L. Cummings

961 papers receiving 100.5k citations

Hit Papers

The Montreal Cognitive As... 1993 2026 2004 2015 2005 1994 1998 2007 1993 5.0k 10.0k 15.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment
    2005 17.1k citations Ziad Nasreddine, Jeffrey L. Cummings et al. profile →
  2. The Neuropsychiatric Inventory
    1994 6.0k citations Jeffrey L. Cummings et al. profile →
  3. Frontotemporal lobar degeneration
    1998 4.0k citations Bruce L. Miller, Jeffrey L. Cummings et al. profile →
  4. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
    2007 3.2k citations Bruno Dubois, Howard Feldman et al. The Lancet Neurology profile →
  5. Frontal-Subcortical Circuits and Human Behavior
    1993 1.8k citations Jeffrey L. Cummings Archives of Neurology profile →
  6. Practice parameter: Early detection of dementia: Mild cognitive impairment (an evidence-based review) [RETIRED]
    2001 1.6k citations Jeffrey L. Cummings et al. profile →
  7. The Neuropsychiatric Inventory
    1997 1.6k citations Jeffrey L. Cummings profile →
  8. Validation of the NPI-Q, a Brief Clinical Form of the Neuropsychiatric Inventory
    2000 1.4k citations Jeffrey L. Cummings et al. profile →
  9. Practice parameter: Management of dementia (an evidence-based review) [RETIRED]
    2001 1.3k citations Jeffrey L. Cummings et al. profile →
  10. Alzheimer's disease
    2015 1.3k citations Kaj Blennow, Christopher C. Rowe et al. profile →
  11. Alzheimer’s disease drug-development pipeline: few candidates, frequent failures
    2014 1.2k citations Jeffrey L. Cummings et al. Alzheimer s Research & Therapy profile →
  12. The Amyloid-β Pathway in Alzheimer’s Disease
    2021 1.1k citations Harald Hampel, Kaj Blennow et al. profile →
  13. Practice parameter: Diagnosis of dementia (an evidence-based review)
    2001 980 citations Jeffrey L. Cummings, Bruce L. Miller et al. profile →
  14. Frontal–subcortical neuronal circuits and clinical neuropsychiatry
    2002 956 citations Jeffrey L. Cummings et al. profile →
  15. Alzheimer's Disease
    2004 886 citations Jeffrey L. Cummings profile →
  16. The Uniform Data Set (UDS): Clinical and Cognitive Variables and Descriptive Data From Alzheimer Disease Centers
    2006 718 citations Jeffrey L. Cummings, Douglas Galasko et al. profile →
  17. The Alzheimer's Disease Centers' Uniform Data Set (UDS)
    2009 690 citations Jeffrey L. Cummings, Douglas Galasko et al. profile →
  18. Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group
    2021 598 citations Bruno Dubois, Nicolas Villain et al. The Lancet Neurology profile →
  19. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease
    2000 591 citations Jeffrey L. Cummings et al. profile →
  20. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody
    2021 580 citations Jeffrey L. Cummings et al. Alzheimer s Research & Therapy profile →
  21. Alzheimer's disease drug development pipeline: 2019
    2019 567 citations Jeffrey L. Cummings et al. Alzheimer s & Dementia Translational Research & Clinical Interventions profile →
  22. Frontal-subcortical circuits and neuropsychiatric disorders
    1994 550 citations Jeffrey L. Cummings et al. profile →
  23. Transferring R&D knowledge: the key factors affecting knowledge transfer success
    2003 540 citations Jeffrey L. Cummings et al. profile →
  24. Alzheimer's disease drug development pipeline: 2018
    2018 539 citations Jeffrey L. Cummings et al. Alzheimer s & Dementia Translational Research & Clinical Interventions profile →
  25. DNA damage is able to induce senescence in tumor cells in vitro and in vivo.
    2002 537 citations Jeffrey L. Cummings et al. profile →
  26. In vitro and in vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancer
    2002 532 citations Jeffrey L. Cummings et al. profile →
  27. Apathy Is Not Depression
    1998 508 citations Jeffrey L. Cummings, Bruce L. Miller et al. profile →
  28. Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial
    2013 481 citations Jeffrey L. Cummings, Stuart Isaacson et al. The Lancet profile →
  29. Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer’s Disease
    2018 471 citations Jeffrey L. Cummings, Bruno Vellas et al. profile →
  30. Alzheimer's disease drug development pipeline: 2022
    2022 425 citations Jeffrey L. Cummings et al. Alzheimer s & Dementia Translational Research & Clinical Interventions profile →
  31. Treatment Combinations for Alzheimer’s Disease: Current and Future Pharmacotherapy Options
    2019 416 citations Jeffrey L. Cummings, Clive Ballard et al. profile →
  32. Alzheimer's disease drug development pipeline: 2020
    2020 407 citations Jeffrey L. Cummings et al. Alzheimer s & Dementia Translational Research & Clinical Interventions profile →
  33. Randomized Trial of Verubecestat for Prodromal Alzheimer’s Disease
    2019 380 citations Jeffrey L. Cummings, Bruno Vellas et al. profile →
  34. Current state of Alzheimer’s fluid biomarkers
    2018 375 citations Richard Batrla, Jeffrey L. Cummings et al. profile →
  35. Alzheimer's disease drug development pipeline: 2017
    2017 374 citations Jeffrey L. Cummings et al. Alzheimer s & Dementia Translational Research & Clinical Interventions profile →
  36. On the path to 2025: understanding the Alzheimer’s disease continuum
    2017 369 citations Jeffrey L. Cummings, Clifford R. Jack et al. Alzheimer s Research & Therapy profile →
  37. Alzheimer's disease drug development pipeline: 2021
    2021 361 citations Jeffrey L. Cummings et al. Alzheimer s & Dementia Translational Research & Clinical Interventions profile →
  38. Drug development in Alzheimer’s disease: the path to 2025
    2016 346 citations Jeffrey L. Cummings, Bruno Dubois et al. Alzheimer s Research & Therapy profile →
  39. The Mild Behavioral Impairment Checklist (MBI-C): A Rating Scale for Neuropsychiatric Symptoms in Pre-Dementia Populations
    2017 322 citations Zahinoor Ismail, Jeffrey L. Cummings et al. profile →
  40. The probabilistic model of Alzheimer disease: the amyloid hypothesis revised
    2021 290 citations Giovanni B. Frisoni, Daniele Altomare et al. Nature reviews. Neuroscience profile →
  41. Alzheimer's disease drug development pipeline: 2023
    2023 279 citations Jeffrey L. Cummings, Yadi Zhou et al. Alzheimer s & Dementia Translational Research & Clinical Interventions profile →
  42. Developing the ATX(N) classification for use across the Alzheimer disease continuum
    2021 205 citations Harald Hampel, Jeffrey L. Cummings et al. Nature Reviews Neurology profile →
  43. Lecanemab in patients with early Alzheimer’s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study
    2022 185 citations Jeffrey L. Cummings et al. Alzheimer s Research & Therapy profile →
  44. New approaches to symptomatic treatments for Alzheimer’s disease
    2021 165 citations Jeffrey L. Cummings profile →
  45. Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer’s Disease
    2023 161 citations Jeffrey L. Cummings et al. profile →
  46. Aducanumab produced a clinically meaningful benefit in association with amyloid lowering
    2021 155 citations Jeffrey L. Cummings, Alireza Atri et al. Alzheimer s Research & Therapy profile →
  47. Anti-Amyloid Monoclonal Antibodies are Transformative Treatments that Redefine Alzheimer's Disease Therapeutics
    2023 145 citations Jeffrey L. Cummings profile →
  48. The Neuropsychiatric Inventory: Development and Applications
    2020 140 citations Jeffrey L. Cummings profile →
  49. Alzheimer's disease drug development pipeline: 2024
    2024 138 citations Jeffrey L. Cummings, Yadi Zhou et al. Alzheimer s & Dementia Translational Research & Clinical Interventions profile →
  50. Aducanumab: Appropriate Use Recommendations Update
    2022 126 citations Jeffrey L. Cummings, Gil D. Rabinovici et al. profile →
  51. Blood-based biomarkers for Alzheimer’s disease: Current state and future use in a transformed global healthcare landscape
    2023 121 citations Harald Hampel, Yan Hu et al. Neuron profile →
  52. Biomarkers in Alzheimer’s disease: role in early and differential diagnosis and recognition of atypical variants
    2023 107 citations Bruno Dubois, Christine A. F. Von Arnim et al. Alzheimer s Research & Therapy profile →
  53. Genetic correlations between Alzheimer’s disease and gut microbiome genera
    2023 95 citations Jeffrey L. Cummings et al. profile →
  54. Burden of Illness in People with Alzheimer's Disease: A Systematic Review of Epidemiology, Comorbidities and Mortality
    2023 76 citations Krista L. Lanctôt, Jeffrey L. Cummings et al. profile →
  55. Brexpiprazole for the Treatment of Agitation in Alzheimer Dementia
    2023 61 citations Jeffrey L. Cummings et al. profile →
  56. evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer’s disease
    2025 40 citations Jeffrey L. Cummings, Alireza Atri et al. Alzheimer s Research & Therapy profile →
  57. Alzheimer's disease drug development pipeline: 2025
    2025 29 citations Jeffrey L. Cummings, Yadi Zhou et al. Alzheimer s & Dementia Translational Research & Clinical Interventions profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jeffrey L. Cummings United States 141 45.3k 30.8k 21.9k 15.7k 11.8k 994 104.0k
John C. Morris United States 148 48.0k 1.1× 44.1k 1.4× 24.6k 1.1× 9.5k 0.6× 15.1k 1.3× 999 116.2k
Bruce L. Miller United States 146 31.9k 0.7× 28.9k 0.9× 28.8k 1.3× 25.4k 1.6× 12.4k 1.1× 1.1k 90.5k
Steven T. DeKosky United States 111 29.5k 0.7× 25.4k 0.8× 11.8k 0.5× 9.6k 0.6× 9.2k 0.8× 549 64.0k
David S. Knopman United States 142 47.4k 1.0× 40.8k 1.3× 23.0k 1.0× 14.2k 0.9× 14.8k 1.3× 1.0k 94.0k
Philip Scheltens Netherlands 137 43.9k 1.0× 36.4k 1.2× 29.8k 1.4× 13.0k 0.8× 18.2k 1.5× 1.2k 100.6k
David A. Bennett United States 148 28.5k 0.6× 32.5k 1.1× 10.0k 0.5× 8.3k 0.5× 12.6k 1.1× 1.3k 86.1k
Ronald C. Petersen United States 157 61.2k 1.4× 51.4k 1.7× 29.4k 1.3× 17.2k 1.1× 18.2k 1.5× 1.1k 117.0k
Guy M. McKhann United States 90 26.7k 0.6× 22.7k 0.7× 14.1k 0.6× 10.8k 0.7× 8.0k 0.7× 452 67.9k
Susan E. Folstein United States 68 35.3k 0.8× 13.4k 0.4× 24.6k 1.1× 11.1k 0.7× 5.3k 0.5× 140 86.9k
Marshal F. Folstein United States 57 37.4k 0.8× 15.5k 0.5× 18.5k 0.8× 10.1k 0.6× 5.7k 0.5× 147 85.1k

Countries citing papers authored by Jeffrey L. Cummings

Since Specialization
Citations

This map shows the geographic impact of Jeffrey L. Cummings's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey L. Cummings with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey L. Cummings more than expected).

Fields of papers citing papers by Jeffrey L. Cummings

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey L. Cummings. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey L. Cummings. The network helps show where Jeffrey L. Cummings may publish in the future.

Co-authorship network of co-authors of Jeffrey L. Cummings

This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey L. Cummings. A scholar is included among the top collaborators of Jeffrey L. Cummings based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey L. Cummings. Jeffrey L. Cummings is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Feng, Yayan, Shuqin Cao, Yi Shi, et al.. (2025). Human herpesvirus‐associated transposable element activation in human aging brains with Alzheimer's disease. Alzheimer s & Dementia. 21(2). e14595–e14595. 3 indexed citations
2.
Shan, Guogen & Jeffrey L. Cummings. (2025). Assessing safety and efficacy in subpopulations in Alzheimer's disease clinical trials: contextualizing representativeness. Alzheimer s & Dementia Translational Research & Clinical Interventions. 11(4). e70186–e70186.
3.
Miller, David S., Daniel R. Bateman, Jeffrey L. Cummings, et al.. (2025). Mapping of validated apathy scales onto the apathy diagnostic criteria for neurocognitive disorders. International Psychogeriatrics. 37(5). 100074–100074.
4.
Lu, Ping, et al.. (2025). Delivery of genome editors with engineered virus-like particles. Methods in enzymology on CD-ROM/Methods in enzymology. 712. 475–516.
5.
Galvin, James E., Jeffrey L. Cummings, Carl de Moor, et al.. (2024). Generating real‐world evidence in Alzheimer's disease: Considerations for establishing a core dataset. Alzheimer s & Dementia. 20(6). 4331–4341. 5 indexed citations
6.
Dubois, Bruno, et al.. (2023). Biomarkers in Alzheimer’s disease: role in early and differential diagnosis and recognition of atypical variants. Alzheimer s Research & Therapy. 15(1). 175–175. 107 indexed citations breakdown →
7.
Nirogi, Ramakrishna, Pradeep Jayarajan, Anil Shinde, et al.. (2023). Progress in Investigational Agents Targeting Serotonin-6 Receptors for the Treatment of Brain Disorders. Biomolecules. 13(2). 309–309. 31 indexed citations
8.
Hampel, Harald, Yan Hu, Jeffrey L. Cummings, et al.. (2023). Blood-based biomarkers for Alzheimer’s disease: Current state and future use in a transformed global healthcare landscape. Neuron. 111(18). 2781–2799. 121 indexed citations breakdown →
9.
Yang, Zhengshi, et al.. (2023). Accelerated hypometabolism with disease progression associated with faster cognitive decline among amyloid positive patients. Frontiers in Neuroscience. 17. 1151820–1151820. 7 indexed citations
10.
Dubois, Bruno, Nicolas Villain, Giovanni B. Frisoni, et al.. (2021). Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group. The Lancet Neurology. 20(6). 484–496. 598 indexed citations breakdown →
11.
Zhou, Yadi, Jiansong Fang, Lynn M. Bekris, et al.. (2021). AlzGPS: a genome-wide positioning systems platform to catalyze multi-omics for Alzheimer’s drug discovery. Alzheimer s Research & Therapy. 13(1). 56 indexed citations
12.
Frisoni, Giovanni B., Daniele Altomare, Dietmar Rudolf Thal, et al.. (2021). The probabilistic model of Alzheimer disease: the amyloid hypothesis revised. Nature reviews. Neuroscience. 23(1). 53–66. 290 indexed citations breakdown →
13.
Hampel, Harald, Jeffrey L. Cummings, Kaj Blennow, et al.. (2021). Developing the ATX(N) classification for use across the Alzheimer disease continuum. Nature Reviews Neurology. 17(9). 580–589. 205 indexed citations breakdown →
14.
Cummings, Jeffrey L., Stuart Isaacson, Roger Mills, et al.. (2013). Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. The Lancet. 383(9916). 533–540. 481 indexed citations breakdown →
15.
Dubois, Bruno, Serge Gauthier, & Jeffrey L. Cummings. (2012). The utility of the new research diagnostic criteria for Alzheimer's disease. International Psychogeriatrics. 25(2). 174–184. 8 indexed citations
16.
Teng, Edmond, John M. Ringman, Leslie Ross, et al.. (2008). Diagnosing Depression in Alzheimer Disease With the National Institute of Mental Health Provisional Criteria. American Journal of Geriatric Psychiatry. 16(6). 469–477. 75 indexed citations
17.
Sobrido, María-Jesús, Bruce L. Miller, Necat Havlioglu, et al.. (2003). Novel Tau Polymorphisms, Tau Haplotypes, and Splicing in Familial and Sporadic Frontotemporal Dementia. Archives of Neurology. 60(5). 698–698. 44 indexed citations
18.
Cummings, Jeffrey L., et al.. (1996). Determination of the novel topoisomerase I inhibitor NU/ICRF 505 and its major metabolite in plasma, tissue and tumour by high-performance liquid chromatography. Journal of Chromatography B Biomedical Sciences and Applications. 685(1). 159–164. 5 indexed citations
19.
Carmel, Ralph, et al.. (1996). Spouses of demented patients with low cobalamin levels: a new risk group for cobalamin deficiency. European Journal Of Haematology. 57(1). 62–67. 6 indexed citations
20.
Friedlander, Arthur H. & Jeffrey L. Cummings. (1992). Dental treatment of patients with Gilles de la Tourette's syndrome. Oral Surgery Oral Medicine Oral Pathology. 73(3). 299–303. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by John C. Morris Breakdown of academic impact, for papers by Bruce L. Miller Breakdown of academic impact, for papers by Steven T. DeKosky Breakdown of academic impact, for papers by David S. Knopman Breakdown of academic impact, for papers by Philip Scheltens Breakdown of academic impact, for papers by David A. Bennett Breakdown of academic impact, for papers by Ronald C. Petersen Breakdown of academic impact, for papers by Guy M. McKhann Breakdown of academic impact, for papers by Susan E. Folstein Breakdown of academic impact, for papers by Marshal F. Folstein
Rankless by CCL
2026